CA2625981A1 - Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof - Google Patents
Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof Download PDFInfo
- Publication number
- CA2625981A1 CA2625981A1 CA002625981A CA2625981A CA2625981A1 CA 2625981 A1 CA2625981 A1 CA 2625981A1 CA 002625981 A CA002625981 A CA 002625981A CA 2625981 A CA2625981 A CA 2625981A CA 2625981 A1 CA2625981 A1 CA 2625981A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- gse
- nucleotide sequence
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000694 effects Effects 0.000 title claims abstract description 168
- 108010017842 Telomerase Proteins 0.000 title claims abstract description 148
- 239000002773 nucleotide Substances 0.000 title claims abstract description 90
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 89
- 102100031249 H/ACA ribonucleoprotein complex subunit DKC1 Human genes 0.000 title claims abstract description 61
- 101710167047 H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 title claims abstract description 50
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 27
- 230000001225 therapeutic effect Effects 0.000 title claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 239000013598 vector Substances 0.000 claims abstract description 52
- 206010062759 Congenital dyskeratosis Diseases 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 230000032683 aging Effects 0.000 claims abstract description 20
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 11
- 230000001133 acceleration Effects 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 231
- 101710137284 Protein STPG4 Proteins 0.000 claims description 108
- 230000014509 gene expression Effects 0.000 claims description 60
- 238000010276 construction Methods 0.000 claims description 53
- 208000009356 dyskeratosis congenita Diseases 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 230000002068 genetic effect Effects 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 18
- 230000004075 alteration Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 101000705925 Homo sapiens Protein STPG4 Proteins 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 10
- 208000004485 Nijmegen breakage syndrome Diseases 0.000 claims description 8
- 210000001766 X chromosome Anatomy 0.000 claims description 8
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010009887 colitis Diseases 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 5
- 208000005692 Bloom Syndrome Diseases 0.000 claims description 5
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 5
- 201000004939 Fanconi anemia Diseases 0.000 claims description 5
- 201000011032 Werner Syndrome Diseases 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 4
- 206010028570 Myelopathy Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 63
- 229960004316 cisplatin Drugs 0.000 description 63
- 238000001890 transfection Methods 0.000 description 27
- 108010069860 GSE24.2 peptide Proteins 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 17
- 230000035772 mutation Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 101000844866 Homo sapiens H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 description 13
- 108060001084 Luciferase Proteins 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 108091035539 telomere Proteins 0.000 description 13
- 102000055501 telomere Human genes 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 230000035899 viability Effects 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 210000003411 telomere Anatomy 0.000 description 11
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 9
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 9
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000007547 defect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108010057210 telomerase RNA Proteins 0.000 description 6
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 5
- 206010065553 Bone marrow failure Diseases 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 108700024542 myc Genes Proteins 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108010049718 pseudouridine synthases Proteins 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 101150028074 2 gene Proteins 0.000 description 4
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 4
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091035710 E-box Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 102000051771 human DKC1 Human genes 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000009010 Bradford assay Methods 0.000 description 2
- 101150016452 CBF5 gene Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108091081406 G-quadruplex Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710128979 23 kDa piroplasm membrane protein Proteins 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 240000006487 Aciphylla squarrosa Species 0.000 description 1
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 101150065175 Atm gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 101150080917 DKC1 gene Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
- 241000275449 Diplectrum formosum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 1
- 101001087045 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 101000659685 Homo sapiens Probable tRNA pseudouridine synthase 1 Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 101000844862 Mus musculus H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 description 1
- 101100206736 Mus musculus Tiam1 gene Proteins 0.000 description 1
- 108050003990 Nibrin Proteins 0.000 description 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 102100036287 Probable tRNA pseudouridine synthase 1 Human genes 0.000 description 1
- 208000032991 Profound mental retardation Diseases 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 101710094326 Ras-related protein R-Ras Proteins 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 229940123582 Telomerase inhibitor Drugs 0.000 description 1
- 102100024553 Telomerase protein component 1 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 101710157927 Translationally-controlled tumor protein Proteins 0.000 description 1
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 102220351956 c.26G>A Human genes 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 101150090832 recQ gene Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 102200015255 rs121912297 Human genes 0.000 description 1
- 102220089505 rs187964306 Human genes 0.000 description 1
- 102220059226 rs759680369 Human genes 0.000 description 1
- 102220086243 rs864622700 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108091064493 tRNA uridine Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502511A ES2325431B1 (es) | 2005-10-14 | 2005-10-14 | Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. |
| ESP200502511 | 2005-10-14 | ||
| PCT/ES2006/070152 WO2007090911A1 (es) | 2005-10-14 | 2006-10-11 | Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2625981A1 true CA2625981A1 (en) | 2007-08-16 |
Family
ID=38344881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002625981A Abandoned CA2625981A1 (en) | 2005-10-14 | 2006-10-11 | Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9074194B2 (enExample) |
| EP (1) | EP1947175B1 (enExample) |
| JP (1) | JP5560398B2 (enExample) |
| AT (1) | ATE469212T1 (enExample) |
| CA (1) | CA2625981A1 (enExample) |
| DE (1) | DE602006014574D1 (enExample) |
| DK (1) | DK1947175T3 (enExample) |
| ES (2) | ES2325431B1 (enExample) |
| PT (1) | PT1947175E (enExample) |
| WO (1) | WO2007090911A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2334736B1 (es) * | 2007-11-23 | 2011-02-02 | Consejo Superior De Investigaciones Cientificas (Titular Al 90%) | Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular. |
| WO2014122346A1 (es) * | 2013-02-05 | 2014-08-14 | Consejo Superior De Investigaciones Cientificas (Csic) | Bionanopartículas biodegradables para liberación del péptido gse24-2, procedimiento de obtención y utilización |
| WO2015059338A1 (es) | 2013-10-25 | 2015-04-30 | Consejo Superior De Investigaciones Científicas (Csic) | Péptidos derivados de gse24.2 para tratar enfermedades producidas por estrés oxidativo y daño al adn |
| WO2020223475A1 (en) * | 2019-05-02 | 2020-11-05 | Board Of Regents, The University Of Texas System | Methods and compositions involving tert activating therapies |
| ES2989543A1 (es) * | 2023-05-22 | 2024-11-26 | Alodia Farm S L U | Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| DE19817118C1 (de) * | 1998-04-17 | 1999-10-28 | Deutsches Krebsforsch | Dyskerin und dafür codierende DNA-Moleküle, diese enthaltende Vektoren, Antikörper gegen Dyskerin und die Verwendung dieser Gegenstände |
-
2005
- 2005-10-14 ES ES200502511A patent/ES2325431B1/es not_active Expired - Fee Related
-
2006
- 2006-10-11 JP JP2008535049A patent/JP5560398B2/ja not_active Expired - Fee Related
- 2006-10-11 EP EP06849419A patent/EP1947175B1/en active Active
- 2006-10-11 ES ES06849419T patent/ES2360238T3/es active Active
- 2006-10-11 DK DK06849419.4T patent/DK1947175T3/da active
- 2006-10-11 AT AT06849419T patent/ATE469212T1/de active
- 2006-10-11 DE DE602006014574T patent/DE602006014574D1/de active Active
- 2006-10-11 US US12/090,215 patent/US9074194B2/en not_active Expired - Fee Related
- 2006-10-11 PT PT06849419T patent/PT1947175E/pt unknown
- 2006-10-11 CA CA002625981A patent/CA2625981A1/en not_active Abandoned
- 2006-10-11 WO PCT/ES2006/070152 patent/WO2007090911A1/es not_active Ceased
-
2015
- 2015-06-16 US US14/740,890 patent/US9587002B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007090911A1 (es) | 2007-08-16 |
| US20150337022A1 (en) | 2015-11-26 |
| JP2009511036A (ja) | 2009-03-19 |
| EP1947175B1 (en) | 2010-05-26 |
| ES2325431A1 (es) | 2009-09-03 |
| PT1947175E (pt) | 2010-09-02 |
| ATE469212T1 (de) | 2010-06-15 |
| ES2325431B1 (es) | 2010-06-28 |
| JP5560398B2 (ja) | 2014-07-23 |
| DK1947175T3 (da) | 2010-09-27 |
| ES2360238T3 (es) | 2011-06-02 |
| DE602006014574D1 (de) | 2010-07-08 |
| US20090202503A1 (en) | 2009-08-13 |
| US9587002B2 (en) | 2017-03-07 |
| EP1947175A1 (en) | 2008-07-23 |
| US9074194B2 (en) | 2015-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chun et al. | Cytosolic Hsp60 is involved in the NF-κB-dependent survival of cancer cells via IKK regulation | |
| US9587002B2 (en) | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof | |
| KR20010020601A (ko) | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 | |
| JP2013056876A (ja) | 抗炎症化合物及びその利用 | |
| CA3009034C (en) | Compositions and methods of using chondroitinase abci mutants | |
| JP5581485B2 (ja) | Ｅｃ−ｓｏｄの新規な用途及びその製造方法 | |
| CA2202519C (en) | Cloning, expression and characterization of a new form of phosphatidylinositol-3-kinase | |
| EP0896055A2 (en) | Apoptosis inducing protein and gene encoding the same | |
| KR102127218B1 (ko) | 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도 | |
| ES2334736B1 (es) | Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular. | |
| Parkinson | Telomerase as a novel and potentially selective target for cancer chemotherapy | |
| KR100399982B1 (ko) | Ａｓｋ１과 결합하는 ｃａｄ의 선택적인 저해제로서아폽토시스를 억제하는 신규한 마우스 ｃｉａ 단백질,ｃｉａ 유전자 및 그의 용도 | |
| Perona Abellón et al. | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof | |
| SÁNCHEZ PÉREZ | TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS | |
| KR102241134B1 (ko) | Fgf2 또는 api5 유래 펩타이드를 발현하는 항암 바이러스 및 이의 용도 | |
| Lepetit et al. | The cloning and characterization of a cDNA encoding Xenopus laevis DNA ligase I | |
| WO2003024997A1 (en) | Telomerase inhibitory peptides and uses thereof | |
| US20030105008A1 (en) | Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses | |
| KR101826249B1 (ko) | 융합 단백질 및 이를 포함하는 세포주기 조절제 | |
| JP2007169223A (ja) | アポトーシス促進剤およびそれを用いた医薬製剤 | |
| US20090047672A1 (en) | Telomerase RNA Subunit and Methods of Use Thereof | |
| Suzanne Lewis | Genetic modification of the human mitotic clock by telomerase: a matter of life and death. | |
| JP2003506081A (ja) | ＮＦ−κＢ活性化に関与するプロテインキナーゼＣ相互作用性タンパク質 | |
| KR20090111728A (ko) | Ｊｎｋ1을 유효성분으로 포함하는 ｎｒｌ-매개 안구질환의예방 및 치료용 약학적 조성물 | |
| AU2002325676A1 (en) | Telomerase inhibitory peptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20200831 |